The remaining reports on developmental processes in this issue highlight two quite different themes. The first is the risks and benefits of drug treatment during pregnancy and the postpartum period. Viguera et al. show that lithium discontinuation during pregnancy is associated with a relapse rate similar to that for lithium discontinuation among nonpregnant patients with bipolar disorder followed over a similar period of time (52% and 58%, respectively). However, the postpartum recurrence is much higher (80%), even for patients who remain stable after lithium discontinuation throughout pregnancy. Given lithium’s well-documented fetal toxicity, a trial discontinuation period at least early in pregnancy would seem generally indicated, as would the need for resumption of the medication postpartum. In many instances of major psychiatric illness, nursing mothers will be maintained on their psychotropic drug regimen. Stowe et al. report on a systematic study in which levels of paroxetine in breast milk and infant serum were examined in relation to maternal paroxetine dose. Encouragingly, infant serum paroxetine was not detectable, and no adverse effects were seen. This unusually well-done study extends a series of earlier reports supporting the safety of selective serotonin reuptake inhibitors during lactation.